This is further supported by a silencing of LFABP in patients with hepatocellular adenoma who had a mutation in the hepatocyte nuclear factor 1α, causing impaired trafficking of fatty acids, leading to steatosis [27]. The gene discussed is FABP1; the disease is hepatocellular adenoma.